How I treat advanced Hodgkin lymphoma - a global view

Affiliations

¹ Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.
² Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
³ Department of Haemato-oncology, Barts Health NHS Trust, London, UK.
⁴ Centre for Haemato-oncology, Barts Cancer Institute, London, UK.
⁵ German Hodgkin Study Group, Department I of Internal Medicine, Center for Integrated Oncology, University of Cologne, Aachen Bonn Cologne Duesseldorf, Köln, Germany.
⁶ Department of Haematology, Christian Medical College, Vellore, India.
⁷ Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
⁸ Haematology Department, Concord Repatriation General Hospital, University of Sydney, Sydney, Australia.

Review

Peter Hokland et al. Br J Haematol. 2020 Sep.

. 2020 Sep;190(6):837-850.

doi: 10.1111/bjh.16587. Epub 2020 Jun 19.

¹ Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark.
² Division of Blood Disorders, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
³ Department of Haemato-oncology, Barts Health NHS Trust, London, UK.
⁴ Centre for Haemato-oncology, Barts Cancer Institute, London, UK.
⁵ German Hodgkin Study Group, Department I of Internal Medicine, Center for Integrated Oncology, University of Cologne, Aachen Bonn Cologne Duesseldorf, Köln, Germany.
⁶ Department of Haematology, Christian Medical College, Vellore, India.
⁷ Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
⁸ Haematology Department, Concord Repatriation General Hospital, University of Sydney, Sydney, Australia.

No abstract available

Conflict of interest statement

Conflict of interest

There are no conflicts to declare.

Correspondence in reference to the previously published Epub manuscript: "Peter Hokland, et al. How I treat advanced Hodgkin lymphoma - a global view. British Journal of Haematology 2020; 190: 837-850." - RESPONSE.
Trotman J, Hokland P. Trotman J, et al. Br J Haematol. 2021 Apr;193(1):e4-e5. doi: 10.1111/bjh.17370. Epub 2021 Feb 22. Br J Haematol. 2021. PMID: 33617674 No abstract available.
Correspondence in reference to the previously published Epub manuscript by Peter Hokland et al. 'How I treat advanced Hodgkin lymphoma - a global view'. Br J Haematol. 2020;190:837-50.
Picardi M, Giordano C, Della Pepa R, Pugliese N, Leone A, Mascolo M, Daniela R, Vigliar E, Troncone G, Salvatore C, Pane F. Picardi M, et al. Br J Haematol. 2021 Apr;193(1):e5-e8. doi: 10.1111/bjh.17371. Epub 2021 Mar 4. Br J Haematol. 2021. PMID: 33660274 No abstract available.

1. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68. - PMC - PubMed
1. Moulin-Romsee G, Hindie E, Cuenca X, Brice P, Decaudin D, Benamor M, et al. (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging. 2010;37:1095–105. - PubMed
1. van der Kaaij MA, van Echten-Arends J, Simons AH, Kluin-Nelemans HC. Fertility preservation after chemotherapy for Hodgkin lymphoma. Hematol Oncol. 2010;28:168–79. - PubMed
1. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer. 1975;36:252–9. - PubMed
1. Skoetz N, Will A, Monsef I, Brillant C, Engert A, von Tresckow B. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev. 2017;5 CD007941. - PMC - PubMed